In March, Amador Bioscience, a translational and consulting clinical research organization, entered into an agreement with Altasciences, a company specializing in an innovative approach to comprehensive early stage drug development. This partnership aims to expand world-class capabilities and resources to promote drug development in both North America and China. Amador Bioscience has also entered into strategic collaborations with leading cancer research hospitals in China to further accelerate transpacific drug development programs.

Amador Bioscience provides global-standard laboratory, clinical research, strategy consulting, and regulatory filing services to leading biopharmaceutical companies. The laboratory services focus on bioanalysis, biomarkers, and immunogenicity assessment. Amador's clinical research unit specializes in innovative clinical development strategy, protocol design, study initiation, and monitoring of clinical studies in China and the United States.

"We are pleased to be partnering with Altasciences, offering our clients access to world-class preclinical and clinical facilities, personalized services, and 25 years' expertise in conducting successful clinical trials," according to Xiaomin Chen, General Manager of Amador Bioscience. "Our synergistic and effective collaboration will surely expedite the development of novel therapeutics."

Amador Bioscience and Altasciences will collaborate on IND-enabling preclinical studies, which are the studies required for approval to conduct human clinical trials with a new drug, as well as design and conduct of early stage clinical programs, including first-in-human and proof-of-concept trials. The companies will also work together to provide end-to-end solutions, such as laboratory services, to transpacific drug development programs.

"We are excited to collaborate with Amador Bioscience's dedicated team of diverse experts, particularly in support of China's fast-growing and innovative biotech industry," according to Steve Mason, Executive Vice President of Altasciences.

Amador offers its clients a highly experienced and well-integrated team of clinical pharmacologists; bioanalytical, translational, and clinical scientists; clinical trial management experts; biostatisticians; regulatory specialists; quality assurance auditors; project managers; and more. It can offer clients support through the technical, operational, quality, compliance, and regulatory phases of preclinical and clinical drug development programs. The company's experts collaborate with more than 20 leading biopharma companies.

In addition to research and development strategy and regulatory services, Amador offers clients global-standard data analysis and generates submission-ready study reports. Amador has successfully supported Common Technical Document (CTD) filings for the pharmaceutical industry in China and the U.S. The US office of Amador Bioscience is located at Hacienda. It also has offices in the cities of Hangzhou and Beijing in China.

For more information about Amador Bioscience, please visit www.amadorbio.com.